^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    MEK1 inhibitor

    Related drugs:
    11d
    A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Clinical Activity of RO7276389 Alone and in Combination with Cobimetinib in Participants with BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with Central Nervous System Metastases (2023-506310-43-00)
    P1, N=70, Completed, F. Hoffmann-La Roche AG | Recruiting --> Completed
    Trial completion
    |
    BRAF (B-raf proto-oncogene)
    |
    Cotellic (cobimetinib)
    1m
    Comparative Proteomic Analysis of the Secretome of Control and BRAF/MEK Inhibitor-Resistant Melanoma Cells. (PubMed, J Proteome Res)
    Therefore, this study aimed to examine the protein composition of the secretome of cells resistant to vemurafenib (a BRAF inhibitor) and cobimetinib (a MEK inhibitor) and to compare it with that of nonresistant cells. Proteins secreted by resistant melanoma cells can undoubtedly influence the surrounding microenvironment in a way that promotes the formation of a pro-tumor niche. Among the proteins secreted in significantly higher amounts by resistant cells (compared to the control group), which may be potential biomarkers or therapeutic targets in melanoma, plasminogen activator inhibitor 1, thymosin beta-4, clusterin, interleukin-6, superoxide dismutase, and selected matrix metalloproteinases can be distinguished.
    Journal
    |
    IL6 (Interleukin 6) • CLU (Clusterin)
    |
    Zelboraf (vemurafenib) • Cotellic (cobimetinib)
    1m
    Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, West China Second University Hospital
    New trial
    |
    CD20 positive
    |
    vincristine • prednisone • Fu Mai Ning (luvometinib) • mercaptopurine
    1m
    A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Clinical Activity of RO7276389 Alone and in Combination with Cobimetinib in Participants with BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with Central Nervous System Metastases (2023-506310-43-00)
    P1, N=70, Recruiting, F. Hoffmann-La Roche AG | -> Recruiting | Phase classification: PN/A --> P1
    Enrollment open • Phase classification
    |
    BRAF (B-raf proto-oncogene)
    |
    Cotellic (cobimetinib)
    1m
    Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas (clinicaltrials.gov)
    P3, N=177, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P3 trial
    |
    NF1 (Neurofibromin 1)
    |
    TQ-B3234
    2ms
    CONCERTO: Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, University of Utah | Trial primary completion date: Jan 2026 --> Apr 2025
    Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BCR (BCR Activator Of RhoGEF And GTPase) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
    |
    BRAF mutation
    |
    Cotellic (cobimetinib)
    2ms
    A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation (clinicaltrials.gov)
    P2, N=18, Terminated, Recursion Pharmaceuticals Inc. | N=60 --> 18 | Trial completion date: Jan 2027 --> Feb 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Feb 2025; Study was terminated due to sponsor decision. This decision was not related to safety concerns.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    APC (APC Regulator Of WNT Signaling Pathway) • RAS (Rat Sarcoma Virus) • AXIN1 (Axin 1)
    |
    REC-4881
    2ms
    A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. (clinicaltrials.gov)
    P1, N=65, Active, not recruiting, Genentech, Inc. | Trial completion date: Dec 2025 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Jun 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation
    |
    Opdivo (nivolumab) • Cotellic (cobimetinib) • belvarafenib (RG6185)
    2ms
    Application Demonstration Program of Luvometinib for Pediatric and Adolescent Patients Aged 2 Years and Older with Symptomatic, Unresectable Plexiform Neurofibromas (PN) Associated with Neurofibromatosis Type 1 (NF1)(Demonstration project for the application of luvometinib in the treatment of neurofibromatosis type 1(rare disease)) (ChiCTR2500115360)
    P4, N=100, Not yet recruiting, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai Jiao Tong University Sc
    New P4 trial
    |
    NF1 (Neurofibromin 1)
    |
    Fu Mai Ning (luvometinib)
    2ms
    Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion. (PubMed, ESMO Open)
    ABM-1310 showed a favorable safety profile and encouraging intracranial activity. These findings support continued evaluation for CNS tumors and in cancer patients with prior BRAF inhibitor exposure.
    P1 data • Journal • First-in-human
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF mutation
    |
    Cotellic (cobimetinib) • ABM-1310
    2ms
    Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions (clinicaltrials.gov)
    P=N/A, N=62, Recruiting, West China Second University Hospital
    New trial
    |
    Fu Mai Ning (luvometinib)
    2ms
    CONCERTO: Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, University of Utah | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BCR (BCR Activator Of RhoGEF And GTPase) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
    |
    BRAF mutation
    |
    Cotellic (cobimetinib)